Johnson & Johnson Inc and Pfizer Inc have announced the termination of their jointly-run investigation of the drug, bapineuzumab, for patients with mild-to-moderate Alzheimer’s disease. This follows the failure of two Phase 3 studies. ---Subscribe to MedNous to access this article--- Clinical Research Company News
